A new research study at UCLA aims to re-define prostate cancer significance through clinical validation of a tool which allows 3D visualization and tracking of the prostate. By fusing multi-parametric MRI (T2-weighted, diffusion-weighted imaging, dynamic contrast enhancement) with real-time ultrasound, suspicious areas seen on the MRI can be tracked and targeted during prostate biopsy. This research aims to improve currently available methods of cancer diagnosis.
Prostate cancer is the second leading cause of cancer death in American men. The UCLA Prostate MR Imaging Group continues to lead the way in prostate imaging and education.
UCLA's own Dr. Daniel Margolis has stated in an article for the Prostate Cancer Research Institute (PCRI) that, "MRI holds tremendous potential to finally help distinguish patients with non-aggressive cancer who do not need treatment from those with aggressive disease who do."
Targeted prostate biopsy was highlighted in the September 2011 issue of the RSNA News: "Fusion Imaging Could Revolutionize Prostate Biopsies".